Worlds apart? A comparison of the new product development strategies of biopharmaceutical firms in europe and the USA

Industry and Innovation

Volumn 16, Issue 6, 2009, Pages 593-612

  Xia, Tianjiao ^a   Roper, Stephen ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Biopharmaceutical; Comparative analysis; Europe; USA

Indexed keywords

COMPARATIVE STUDY; EUROPEAN UNION; INDUSTRIAL COMPETITION; INDUSTRIAL POLICY; PHARMACEUTICAL INDUSTRY; PRODUCT DEVELOPMENT; RESEARCH AND DEVELOPMENT;

FRANCE; GERMANY; UNITED KINGDOM; UNITED STATES;

EID: 72149089002     PISSN: 13662716     EISSN: 14698390     Source Type: Journal    
DOI: 10.1080/13662710903371108     Document Type: Article

References (113)

1. Acs, Z. J. and Audretsch, D. B. (1989) Patents as a measure of innovative activity, Kyklos, 42(2), pp. 171-180.
2. Amir-Aslani, A. and Negassi, S. (2006) Is technology integration the solution to biotechnology's low research and development productivity?, Technovation, 26, pp. 573-582.
3. Aoki, M. (1990) Towards an economic model of the Japanese firm, Journal of Economic Perspectives, 28, pp. 1-27.
4. Arora, A. and Fosfuri, A. (2003) Licensing the market for technology, Journal of Economic Behavior & Organization, 52, pp. 277-295.
5. Audretsch, D. (2001) The role of small firms in US biotechnology clusters, Small Business Economics, 17(3), pp. 3-15.
6. Azzone, G. and Dalla Pozza, I. (2003) An integrated strategy for launching a new product in the biotech industry, Management Decision, 41(9), pp. 832-843.
7. Bagchi-Sen, S., Lawton, H. and Hall, L. (2004) The US biotechnology industry: industry dynamics and policy, Environment and Planning C: Government and Policy, 22, pp. 199-216.
8. Bains, W. (2006) What you give is what you get: investment in European biotechnology, Journal of Commercial Biotechnology, 12(4), pp. 274-283.
9. Baptista, R. and Swann, P. (1998) Do firms in clusters innovate more?, Research Policy, 27(5), pp. 525-540.
10. Benner, M. and Sandström, U. (2000) Inertia and change in Scandinavian public-sector research systems: the case of biotechnology, Science and Public Policy, 27, pp. 443-454.
11. BioWorld (2007) BioWorld Phase III Quarterly Report, AHC Media LLC.
12. Boer, H., Caffyn, S., Corso, M., Coughlan, P., Gieskes, J., Magnusson, M., Pavesi, S. and Ronchi, S. (2001) Knowledge and continuous innovation. The CIMA methodology, International Journal of Operations & Production Management, 21(4), pp. 490-503.
13. Calabrese, T., Baum, J. A. C. and Sliverman, B. S. (2000) Canadian biotechnology start-ups, 1991-1997: the role of incumbents' patents and strategic alliances in controlling competition, Social Science Research, 29, pp. 503-534.
14. Casper, S. and Kettler, H. (2001) National institutional frameworks and the hybridisation of entrepreneurial business models: the German and UK biotechnology sectors, Industry and Innovation, 8(1), pp. 5-30.
15. Casper, S. and Matraves, C. (2003) Institutional frameworks and innovation in the German and UK pharmaceutical industry, Research Policy, 32, pp. 1865-1879.
16. Casper, S. and Whitley, R. (2004) Managing competences in entrepreneurial technology firms: a comparative institutional analysis of Germany, Sweden and the UK, Research Policy, 33, pp. 89-106.
17. Chesbrough, H. (2003) Open Innovation: The New Imperative for Creating and Profiting from Technology (Boston, MA: Harvard Business School).
18. Clarysse, B., Wright, M., Lockett, A., Van de Velde, E. and Vohora, A. (2005) Spinning out new ventures: a typology of incubation strategies from European research institutions, Journal of Business Venturing, 20, pp. 183-216.
19. Clarysse, B., Wright, M., Lockett, A., Mustar, P. and Knockaert, M. (2007) Academic spin-offs, formal technology transfer and capital raising, Industrial and Corporate Change, 16(4), pp. 609-640.
20. Cooke, P. (2001) New economy innovation systems: biotechnology in Europe and the USA, Industry and Innovation, 8(3), pp. 267-289.
21. Coombs, J. E. and Deeds, D. L. (2000) title typecontributorInternational alliances as sources of capital: evidence from the biotechnology industry/title, Journal of High Technology Management Research, 11(2), pp. 235-253.
22. Cooper, R. G. (1984) The strategy-performance link in product innovation, R&D Management, 14, pp. 247-259.
23. Critical I (2006) Biotechnology in Europe. Critical I comparative study for EuropaBio
24. D'Aveni, R. A. (1994) Hypercompetition: Managing the Dynamics of Strategic Maneuvering (New York: Free Press).
25. Da Rin, M. and Penas, F. M. (2007) The effect of venture capital on innovation strategies, NBER Working Papers 13636, National Bureau of Economic Research, Inc.
26. Dahlgren, H. and Valentin, F. (2009) Shaken, not stirred: the re-combinatorial capacity of high-tech regions redeployment of resources released from the downsizing of a lead pharmaceutical firm, Industry and Innovation, 16(1), pp. 33-58.
27. De Looze, M. A., Coronini, R. and Joly, P. B. (2001) A note on recent trends in knowledge creation and appropriation through genomics: a scientometric analysis, International Journal of Biotechnology, 3(1/2), pp. 4-22.
28. Deeds, D. L. and Hill, C. W. L. (1996) Strategic alliances and the rate of new product development: an empirical study of entrepreneurial biotechnology firms, Journal of Business Venturing, 11(1), pp. 41-55.
29. Dimsdale, N. and Prevezer, M. (1994) Capital Markets and Corporate Governance (Oxford: Oxford University Press).
30. Dosi, G. (1982) Technological paradigms and technological trajectories, Research Policy, 11, pp. 147-162.
31. Dosi, G., Llerena, P. and Sylos Labini, P. (2006) The relationships between science, technologies and their industrial exploitation: an illustration through the myths and realities of the so called "European Paradox", Research Policy, 35(10), pp. 1450-1464.
32. Dunning, J. H. (1997) Governments and the macro-organization of economic activity: an historical and spatial perspective, Review of International Political Economy, 4(1), pp. 42-86.
33. Engel, D. and Keilbach, M. (2007) Firm-level implications of early stage venture capital investment-an empirical investigation, Journal of Empirical Finance, 14, pp. 150-167.
34. Ernst & Young (1995) European Biotech 95: Gathering Momentum (Brussels: Ernst & Young).
35. Ernst & Young (1996) European Biotech 96-Volatility and Value (Paulo Alto, CA: Ernst & Young LLP).
36. Ernst & Young (1997a) Biotech 97: The Eleventh Industry Annual Report (Paulo Alto, CA: Ernst & Young LLP).
37. Ernst & Young (1997b) European Biotech 97: A New Economy (Paulo Alto, CA: Ernst & Young LLP).
38. Ernst & Young (1998) New Direction's 98 (Paulo Alto, CA: Ernst & Young LLP).
39. Ernst & Young (1999) Biotech 99: Bridging the Gap (Paulo Alto, CA: Ernst & Young LLP).
40. Ernst & Young (2000) Convergence the Biotechnology Industry Report (Paulo Alto, CA: Ernst & Young LLP).
41. Ernst & Young (2001) Integration-Ernst & Young's Eighth Annual Life Sciences Report 2001 (London: Ernst & Young).
42. Ernst & Young (2003) Beyond Borders-Global Biotechnology Report 2003 (Paulo Alto, CA: Ernst & Young LLP).
43. Ernst & Young (2005) Beyond Borders-Global Biotechnology Report 2005 (Paulo Alto, CA: Ernst & Young LLP).
44. Ernst & Young (2006) Beyond Borders-Global Biotechnology Report 2006. Back on Track "The European Perspective" (Paulo Alto, CA: Ernst & Young LLP).
45. Ernst & Young (2007) Beyond Borders-Global Biotechnology Report 2007 (Paulo Alto, CA: Ernst & Young LLP).
46. Ernst & Young (2008) Beyond Borders-Global Biotechnology Report 2008 (Paulo Alto, CA: Ernst & Young LLP). European Commission (2000) Lisbon Agenda, Lisbon.
47. European Venture Capital Association (2007) EVCA Annual Report. Brussels: European Venture Capital Association.
48. European Venture Capital Association (2008) EVCA Annual Report. Brussels: European Venture Capital Association.
49. Fazeli, S. (2004) 2003: what lessons for European biotechnology?, Journal of Commercial Biotechnology, 10(4), pp. 304-311.
50. Fazeli, S. (2005) The European biotech sector: could it achieve more?, Journal of Commercial Biotechnology, 12(1), pp. 10-19.
51. Fosfuri, A. and Tribo, J. A. (2008) Exploring the antecedents of potential absorptive capacity and its impact on innovation performance, Omega, 36(2), pp. 173-187.
52. Garnsey, E. and Leong, Y. Y. (2008) Combining resource-based and evolutionary theory to explain the genesis of bio-networks, Industry and Innovation, 15(6), pp. 669-686.
53. George, G., Zahra, S. and Wood, R. D. (2002) The effects of business-university alliances on innovative output and financial performance: a study of publicly traded biotechnology companies, Journal of Business Venturing, 17, pp. 577-609.
54. Gilsing, V. and Nooteboom, B. (2006) Exploration and exploitation in innovation systems: the case of pharmaceutical biotechnology, Research Policy, 35, pp. 1-23.
55. Griffin, E. M. (1997) A First Look at Communication Theory (New York: McGraw-Hill).
56. Hagedoorn, J. (1993) Understanding the rationale of strategic technology partnering: inter-organizational modes of cooperation and sectoral differences, Strategic Management Journal, 14(5), pp. 371-385.
57. Hall, L. A. and Bagchi-Sen, S. (2001) An analysis of R&D, innovation and business performance in the US biotechnology industry, International Journal of Biotechnology, 3(3/4), pp. 267-286.
58. Hall, L. A. and Bagchi-Sen, S. (2007) An analysis of firm-level innovation strategies in the US biotechnology industry, Technovation, 27, pp. 4-14.
59. Hill, C. W. L. (1997) Establishing a standard: competitive strategy and technological standards in winner-take-all industries, Academy of Management Executive, 11, pp. 7-25.
60. Hollingsworth, R. (1997) Continuities and changes in social systems of production: the cases of Germany, Japan, and the United States, in: R. Hollingsworth & R. Boyer (Eds), Contemporary Capitalism, pp. 265-318 (Cambridge: Cambridge University Press).
61. Kenney, M. (1986) Biotechnology: The University-Industrial Complex (New Haven, CT: Yale University Press).
62. Khanin, D., Baum, J. R., Mahto, R. V. and Heller, C. (2008) Venture capitalists' investment criteria: 40 years of research, Small Business Institute Research Review, 35, pp. 187-192.
63. Kollmer, H. and Dowling, M. (2004) Licensing as a commercialization strategy for new technology-based firms, Research Policy, 33, pp. 1141-1151.
64. Lemarié, S., de Looze, M. A. and Mangematin, V. (2000) Strategies of European 24 SMEs in biotechnology: the role of size, technology and market, Scientometrics, 47(3), pp. 541-560.
65. Lieberman, M. B. and Montgomery, D. B. (1988) First-mover advantages, Strategic Management Journal, 9, pp. 41-58.
66. Lockett, A. and Wright, M. (2005) Resources, capabilities, risk capital and the creation of university spin-out companies, Research Policy, 34, pp. 1043-1057.
67. Lockett, A., Wright, M. and Franklin, S. (2003) Technology transfer and universities' spin-out strategies, Small Business Economics, 20(2), pp. 185-200.
68. Mason, C. M. and Harrison, R. T. (2001) "Investment readiness": a critique of government proposal to increase the demand for venture capital, Regional Studies: The Journal of the Regional Studies Association, 35(7), pp. 663-668.
69. Mason, C. M. and Harrison, R. T. (2004) Improving access to early stage venture capital in regional economies: a new approach to investment readiness, Local Economy, 19(2), pp. 159-173.
70. Maurer, I. and Ebers, M. (2006) Dynamics of social capital and their performance implications: lessons from biotechnology start-ups, Administrative Science Quarterly, 51, pp. 262-292.
71. Miller, J. (2004) Early development still driving CRO performance, Pharmaceutical Technology, 28(9), p. 100.
72. Mohan, S. R. and Rao, A. R. (2005) Strategy for technology development in public R&D institutes by partnering with the industry, Technovation, 25, pp. 1484-1491.
73. Mowery, D. C. and Nelson, R. R. (1999) Sources of Industrial Leadership: Studies of Seven Industries (Cambridge: Cambridge University Press).
74. Mowery, D. C. and Rosenberg, N. (1989) Technology and Pursuit of Economic Growth (New York: Cambridge University Press).
75. Naomi, R. L. and Sokoloff, K. L. (2007) Financing Innovation in the United States: 1870 to the Present (Cambridge, MA: Massachusetts Institute of Technology).
76. NEDO (National Economic Development Office) (1991) New Life for Industry: Biotechnology, Industry and the Community in the 1990s and Beyond (London: National Economic Development Council).
77. Nooteboom, B. (2000) Learning and Innovation in Organizations and Economies (Oxford: Oxford University Press).
78. Oliver, C. (1997) Sustainable competitive advantage: combining institutional and resource-based views, Strategic Management Journal, 18(9), pp. 697-713.
79. Orsenigo, L. (1989) The Emergence of Biotechnology (London: Pinter).
80. Owen-Smith, J, Riccaboni, M., Pammolli, F. and Powell, W. W. (2002) A comparison of U.S. and European university-industry relations in the life sciences, Management Science, 48(1), pp. 24-43.
81. Pierrakis, Y. and Mason, C. (2008) Shifting Sands: The Changing Nature of the Early Stage Venture Capital Market in the UK (London: NESTA).
82. Powell, W. W. and Brantley, P. (1992) Competitive cooperation in biotechnology: learning through networks?, in: N. Nohria & R. G. Eccles (Eds), Networks and Organizations. Structure, Form and Action, pp. 366-394 (Boston, MA: Harvard Business School Press).
83. Powell, W. W., Koput, K. and Smith-Doerr, L. (1996) Inter-organizational collaboration and the locus of innovation: networks of learning in biotechnology, Administrative Science Quarterly, 41, pp. 116-145.
84. Prevezer, M. (2001) Ingredients in the early development of the U.S. biotechnology industry, Small Business Economics, 17, pp. 17-29.
85. Quintana-Garcia, C. and Benavides-Velasco, C. A. (2004) Cooperation, competition, and innovation capability: a panel data of European dedicated biotechnology firms, Technovation, 24, pp. 927-938.
86. Recombinant Capital (2005) Allicense 2005 (San Francisco: Recombinant Capital Inc.).
87. Roper, S., Youtie, J., Shapira, P. and Fernandez-Ribas, A. (forthcoming) Knowledge, capabilities and manufacturing innovation: a US-Europe comparison, Regional Studies.
88. Rosenberg, N. (1982) Inside the Black Box: Technology and Economics (New York: Cambridge University Press).
89. Rothaermel, F. T. (2001) Complementary assets, strategic alliances, and incumbent's advantage: an empirical study of industry and firm effects in the biopharmaceutical industry, Research Policy, 30, pp. 1235-1251.
90. Rothaermel, F. T. and Deeds, D. L. (2004) Exploration and exploitation alliances in biotechnology: a system of new product development, Strategic Management Journal, 25(3), pp. 201-221.
91. Rothaermel, F. T. and Deeds, D. (2006) Alliance type, alliance experience and alliance management capability in high-technology ventures, Journal of Business Venturing, 21, pp. 429-460.
92. Ruckman, K. (2008) Externally sourcing research through acquisition: should it supplement or substitute for internal research?, Industry and Innovation, 15(6), pp. 627-645.
93. Sapir, A. (2003) An agenda for a growing europe-making the EU economic system deliver. Report, July.
94. Scherer, F. M. (1980) Industrial Market Structure and Economic Performance, 2nd edn (Chicago: Rand McNally).
95. Shan, W. (1990) An empirical analysis of organizational strategies by entrepreneurial high technology firms, Strategic Management Journal, 11(2), pp. 129-139.
96. Shan, W. J. and Song, J. Y. (1997) Foreign direct investment and sourcing of technological advantage: evidence from the biotechnology industry, Journal of International Business Studies, 28(2), pp. 267-284.
97. Shan, W., Walker, G. and Kogut, B. (1994) Inter firm cooperation and startup innovation in the biotechnology industry, Strategic Management Journal, 15(5), pp. 387-394.
98. Sharp, M. (1985) The new biotechnology: European governments in search of a strategy. Sussex European Papers No. 15, University of Sussex, Brighton.
99. Sharp, M. (1995) The science of nations: European multinationals and American biotechnology. Paper for the Foundation for Manufacturing and Industry, Institute of Civil Engineers, Mimeo Science Policy Research Unit, Sussex University, Brighton.
100. Siegel, D. S., Veugelers, R. and Wright, M. (2007) Technology transfer offices and commercialization of university intellectual property: performance and policy implications, Oxford Review of Economic Policy, 23(4), pp. 640-660.
101. Soskice, D. (1994) Innovation strategies of companies: a comparative institutional analysis of some cross-country differences, in: W. Zapf (Ed.), Institutionvergleich und Institutionsdynamik, pp. 271-289 (Berlin: Sigma).
102. Soskice, D. (1997) German technology policy, innovation, and national institutional frameworks, Industry and Innovation, 4, pp. 75-96.
103. Soskice, D. (1999) Divergent production regimes: coordinated and uncoordinated market economies in the 1980s and 1990s, in: H. Kitschelt, P. Lange, G. Marks & J. D. Stephens (Eds), Continuity and Change in Contemporary Capitalism, pp. 101-134 (New York: Cambridge University Press).
104. Stevens, A. and Burley, J. (1997) 3000 raw ideas 1/41 commercial success, Research and Technology Management, 40, pp. 16-27.
105. Streiffer, R. (2006) Academic freedom and academic-industry relationships in biotechnology, Kennedy Institute of Ethics Journal, 16(2), pp. 129-149.
106. Teece, D. J. (1986) Profiting from technological innovation: implications for integration, collaboration, licensing and public policy, Research Policy, 15, pp. 285-305.
107. Teece, D. J. (1994) Information sharing, innovation, and antitrust, Antitrust Law Journal, 62(2), pp. 465-481.
108. Terziovski, M. and Morgan, J. P. (2006) Management practices and strategies to accelerate the innovation cycle in the biotechnology industry, Technovation, 26, pp. 545-552.
109. Valikangas, L. and Merlyn, P. (2002) How market-based organization sustains organic innovation, Business Strategy Review, 13(3), pp. 3-6.
110. Vohora, A., Wright, M. and Lockett, A. (2004) Critical junctures in the development of university high-tech spinout companies, Research Policy, 33, pp. 147-175.
111. Whitehead, G. (2003) Early stage and seed financing for biotechnology start-ups: a UK perspective, Journal of Commercial Biotechnology, 9(3), pp. 242-248.
112. Wolter, K. (2003) Can the U.S. experience be repeated? The evolution of biotechnology in three European regions. Mimeo, Duisburg University, Germany.
113. Wright, M., Lockett, A., Clarysse, B. and Binks, M. (2006) University spin-out companies and venture capital, Research Policy, 35, pp. 481-501.